| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:48 UTC |
|---|
| HMDB ID | HMDB0014944 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Pentoxifylline |
|---|
| Description | Pentoxifylline, also known as pentoxil or trental, belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety. Contraindications include intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral haemorrhage, and risk factors for haemorrhage. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and blood clot formation. Pentoxifylline is a drug which is used for the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs. There is some evidence that pentoxifylline can lower the levels of some biomarkers in non-alcoholic steatohepatitis but evidence is insufficient to determine if the drug is safe and effective for this use. However, pentoxifylline is also recommended for off-label use as an adjunct to compression bandaging for the treatment of chronic venous leg ulcers by the Scottish Intercollegiate Guidelines Network) (SIGN) as this has been shown to improve healing rates. Pentoxifylline, in combination with tocopherol and clodronate, has been found to heal refractory osteoradionecrosis of the jaw,and to be prophylactic against osteoradionecrosis. Like other methylated xanthine derivatives, pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. Human studies have been conducted for Peyronie's disease. Pentoxifylline is an extremely weak basic (essentially neutral) compound (based on its pKa). This is its only FDA, MHRA and TGA-labelled indication. Pentoxifylline has also been shown to be of benefit in alcoholic hepatitis, with some studies demonstrating a reduction in risk of hepatorenal syndrome. In a Cochrane systematic review on the use of Pentoxifylline for intermittent claudication in 2015, the following was concluded "The quality of included studies was generally low, and very large variability between studies was noted in reported findings including duration of trials, doses of pentoxifylline and distances participants could walk at the start of trials. Most included studies did not report on randomisation techniques or how treatment allocation was concealed, did not provide adequate information to permit judgement of selective reporting and did not report blinding of outcome assessors. Given all these factors, the role of pentoxifylline in intermittent claudication remains uncertain, although this medication was generally well tolerated by participants". It is generic and sold under many brand names worldwide. Animal studies have been conducted exploring the use of pentoxifylline for erectile dysfunction and hearing loss. |
|---|
| Structure | CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Pentoxil | Kegg | | Trental | Kegg | | EHT0201 | HMDB | | Agapurin | HMDB | | Torental | HMDB | | Oxpentifylline | HMDB |
|
|---|
| Chemical Formula | C13H18N4O3 |
|---|
| Average Molecular Weight | 278.307 |
|---|
| Monoisotopic Molecular Weight | 278.137890462 |
|---|
| IUPAC Name | 3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione |
|---|
| Traditional Name | pentoxifylline |
|---|
| CAS Registry Number | 6493-05-6 |
|---|
| SMILES | CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C |
|---|
| InChI Identifier | InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 |
|---|
| InChI Key | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Imidazopyrimidines |
|---|
| Sub Class | Purines and purine derivatives |
|---|
| Direct Parent | Xanthines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Xanthine
- 6-oxopurine
- Purinone
- Alkaloid or derivatives
- Pyrimidone
- N-substituted imidazole
- Pyrimidine
- Azole
- Imidazole
- Heteroaromatic compound
- Vinylogous amide
- Lactam
- Ketone
- Urea
- Azacycle
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 105 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 5.17 g/L | Not Available | | LogP | 0 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.76 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.6873 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.51 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1920.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 243.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 141.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 159.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 93.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 322.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 396.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 71.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 878.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 411.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1138.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 249.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 299.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 384.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 201.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 14.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Pentoxifylline,1TMS,isomer #1 | CC(=CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C | 2442.5 | Semi standard non polar | 33892256 | | Pentoxifylline,1TMS,isomer #1 | CC(=CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C | 2442.5 | Standard non polar | 33892256 | | Pentoxifylline,1TMS,isomer #1 | CC(=CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C | 3384.4 | Standard polar | 33892256 | | Pentoxifylline,1TMS,isomer #2 | C=C(CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C | 2396.6 | Semi standard non polar | 33892256 | | Pentoxifylline,1TMS,isomer #2 | C=C(CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C | 2377.3 | Standard non polar | 33892256 | | Pentoxifylline,1TMS,isomer #2 | C=C(CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C | 3437.2 | Standard polar | 33892256 | | Pentoxifylline,1TBDMS,isomer #1 | CC(=CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C(C)(C)C | 2661.7 | Semi standard non polar | 33892256 | | Pentoxifylline,1TBDMS,isomer #1 | CC(=CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C(C)(C)C | 2655.2 | Standard non polar | 33892256 | | Pentoxifylline,1TBDMS,isomer #1 | CC(=CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C(C)(C)C | 3392.5 | Standard polar | 33892256 | | Pentoxifylline,1TBDMS,isomer #2 | C=C(CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C(C)(C)C | 2637.0 | Semi standard non polar | 33892256 | | Pentoxifylline,1TBDMS,isomer #2 | C=C(CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C(C)(C)C | 2578.7 | Standard non polar | 33892256 | | Pentoxifylline,1TBDMS,isomer #2 | C=C(CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O)O[Si](C)(C)C(C)(C)C | 3433.6 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Pentoxifylline GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-9480000000-5858a0a94add96d62994 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Pentoxifylline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Pentoxifylline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline LC-ESI-qTof , Positive-QTOF | splash10-001r-2900000000-d54457aaede5317cef72 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline , positive-QTOF | splash10-0059-1890000000-c9be2fe26b2862cba4f5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline , positive-QTOF | splash10-001r-2900000000-d54457aaede5317cef72 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline LC-ESI-QFT , positive-QTOF | splash10-0059-2970000000-95d1edcd63b61b13b22e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 35V, Positive-QTOF | splash10-0059-2970000000-0c35991320854cec88dd | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 50V, Positive-QTOF | splash10-0019-0900000000-dd015a4509f33caa03c0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 40V, Positive-QTOF | splash10-001r-0900000000-65fb6e1754eabaf86ab4 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 35V, Positive-QTOF | splash10-001r-3910000000-848959253dccbbc260a7 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 10V, Positive-QTOF | splash10-004i-0090000000-4f61bb0b4f8342199149 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 30V, Positive-QTOF | splash10-001i-0900000000-79465a5f4259ad7a5fd7 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pentoxifylline 20V, Positive-QTOF | splash10-001i-0940000000-a097189c3d45a68b6674 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 10V, Positive-QTOF | splash10-01t9-0090000000-e92064736a2f3e194af7 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 20V, Positive-QTOF | splash10-03fr-1590000000-3aa22ac7d56a3f0cb967 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 40V, Positive-QTOF | splash10-001i-9300000000-9e889c5028746f141557 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 10V, Negative-QTOF | splash10-004i-0390000000-a66c81c066b3055aee27 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 20V, Negative-QTOF | splash10-004i-2790000000-10e4eef90ade382bc5f4 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 40V, Negative-QTOF | splash10-052f-9500000000-23bd0511497da2b1fc18 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 10V, Positive-QTOF | splash10-004i-0390000000-3e633d64da435129d91b | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 20V, Positive-QTOF | splash10-001i-0910000000-285222c9846c41ea2ed2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 40V, Positive-QTOF | splash10-03di-3900000000-3902c6584393e2a548ed | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 10V, Negative-QTOF | splash10-004i-0290000000-2d198d549fd71c261d88 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 20V, Negative-QTOF | splash10-004i-1930000000-cbb2368f24d9797f040a | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pentoxifylline 40V, Negative-QTOF | splash10-056r-5950000000-89a80796e36b81a0c4a3 | 2021-10-11 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|